secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2026-06-04T20:45:20+00:00
Accession:  0001193125-26-257593
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRSP shareholders approve 2026 equity plan, re-elect all directors at AGM
-------------------------------------------------------------------------

- Shareholders approved 2026 Stock Option and Incentive Plan, reserving shares from prior 2018 plan plus forfeited awards.
- All 11 director nominees re-elected; Samarth Kulkarni re-elected chairman. Ali Behbahani received 35.5M for vs 13.2M against.
- Amendments to articles of association approved, effective June 5, 2026 upon registration in Zug commercial register.
- Ernst & Young AG and Ernst & Young LLP re-elected as statutory auditor and independent registered public accounting firm for FY2026.
- Binding votes passed for board and executive compensation; equity grant for executive committee received ~69% support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526257593/0001193125-26-257593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526257593/crsp-20260604.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer